Crystalys Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $205M
Overview
Uses AI-driven structural biology to design small molecule drugs for hard-to-drug targets.
OncologyNeuroscience
Technology Platform
An integrated AI and structural proteomics platform that models protein-ligand interactions to design novel small molecules for difficult biological targets.
Funding History
1Total raised:$205M
Venture$205M
Opportunities
Potential to rapidly generate valuable intellectual property and drug candidates for high-value targets that have eluded traditional discovery methods.
Risk Factors
High risk of algorithmic failure to produce clinically viable compounds and intense competition for talent and partnerships in the AI-biotech space.
Competitive Landscape
Competes in the rapidly growing AI-driven drug discovery sector, requiring differentiation through unique data sets, algorithms, or target class expertise.